The pharmacology of adrenomedullin 2/intermedin

Yanguo Hong, Debbie L. Hay, Remi Quirion, David R. Poyner

Research output: Contribution to journalArticle

Abstract

Adrenomedullin 2 (AM2) or intermedin is a member of the calcitonin gene-related peptide (CGRP)/calcitonin family of peptides and was discovered in 2004. Unlike other members of this family, no unique receptor has yet been identified for it. It is extensively distributed throughout the body. It causes hypotension when given peripherally, but when given into the CNS, it increases blood pressure and causes sympathetic activation. It also increases prolactin release, is anti-diuretic and natriuretic and reduces food intake. Whilst its effects resemble those of AM, it is frequently more potent. Some characterization of AM2 has been done on molecularly defined receptors; the existing data suggest that it preferentially activates the AM receptor formed from calcitonin receptor-like receptor and receptor activity modifying protein 3. On this complex, its potency is generally equivalent to that of AM. There is no known receptor-activity where it is more potent than AM. In tissues and in animals it is frequently antagonised by CGRP and AM antagonists; however, situations exist in which an AM2 response is maintained even in the presence of supramaximal concentrations of these antagonists. Thus, there is a partial mismatch between the pharmacology seen in tissues and that on cloned receptors. The only AM2 antagonists are peptide fragments, and these have limited selectivity. It remains unclear as to whether novel AM2 receptors exist or whether the mismatch in pharmacology can be explained by factors such as metabolism. © 2011 The British Pharmacological Society.
Original languageEnglish
Pages (from-to)110-120
Number of pages11
JournalBritish Journal of Pharmacology
Volume166
Issue number1
Early online date10 Apr 2012
DOIs
Publication statusPublished - May 2012

Fingerprint

Adrenomedullin
Pharmacology
Calcitonin Gene-Related Peptide
Receptor Activity-Modifying Protein 3
Calcitonin Receptor-Like Protein
Adrenomedullin Receptors
Peptide Fragments
Calcitonin
Diuretics
Prolactin
Hypotension
Eating
Blood Pressure
Peptides

Keywords

  • calcitonin
  • CGRP
  • adrenomedullin
  • intermedin
  • amylin
  • calcitonin receptor-like receptor
  • RAMP
  • receptor activity-modifying protein
  • prolactin
  • hypotension

Cite this

Hong, Yanguo ; Hay, Debbie L. ; Quirion, Remi ; Poyner, David R. / The pharmacology of adrenomedullin 2/intermedin. In: British Journal of Pharmacology. 2012 ; Vol. 166, No. 1. pp. 110-120.
@article{c1f3d34904d04aa58796b544b7dab029,
title = "The pharmacology of adrenomedullin 2/intermedin",
abstract = "Adrenomedullin 2 (AM2) or intermedin is a member of the calcitonin gene-related peptide (CGRP)/calcitonin family of peptides and was discovered in 2004. Unlike other members of this family, no unique receptor has yet been identified for it. It is extensively distributed throughout the body. It causes hypotension when given peripherally, but when given into the CNS, it increases blood pressure and causes sympathetic activation. It also increases prolactin release, is anti-diuretic and natriuretic and reduces food intake. Whilst its effects resemble those of AM, it is frequently more potent. Some characterization of AM2 has been done on molecularly defined receptors; the existing data suggest that it preferentially activates the AM receptor formed from calcitonin receptor-like receptor and receptor activity modifying protein 3. On this complex, its potency is generally equivalent to that of AM. There is no known receptor-activity where it is more potent than AM. In tissues and in animals it is frequently antagonised by CGRP and AM antagonists; however, situations exist in which an AM2 response is maintained even in the presence of supramaximal concentrations of these antagonists. Thus, there is a partial mismatch between the pharmacology seen in tissues and that on cloned receptors. The only AM2 antagonists are peptide fragments, and these have limited selectivity. It remains unclear as to whether novel AM2 receptors exist or whether the mismatch in pharmacology can be explained by factors such as metabolism. {\circledC} 2011 The British Pharmacological Society.",
keywords = "calcitonin, CGRP, adrenomedullin, intermedin, amylin, calcitonin receptor-like receptor, RAMP, receptor activity-modifying protein, prolactin, hypotension",
author = "Yanguo Hong and Hay, {Debbie L.} and Remi Quirion and Poyner, {David R.}",
note = "{\circledC} 2011 The Authors. British Journal of Pharmacology {\circledC} 2011 The British Pharmacological Society.",
year = "2012",
month = "5",
doi = "10.1111/j.1476-5381.2011.01530.x",
language = "English",
volume = "166",
pages = "110--120",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "1",

}

The pharmacology of adrenomedullin 2/intermedin. / Hong, Yanguo; Hay, Debbie L.; Quirion, Remi; Poyner, David R.

In: British Journal of Pharmacology, Vol. 166, No. 1, 05.2012, p. 110-120.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The pharmacology of adrenomedullin 2/intermedin

AU - Hong, Yanguo

AU - Hay, Debbie L.

AU - Quirion, Remi

AU - Poyner, David R.

N1 - © 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

PY - 2012/5

Y1 - 2012/5

N2 - Adrenomedullin 2 (AM2) or intermedin is a member of the calcitonin gene-related peptide (CGRP)/calcitonin family of peptides and was discovered in 2004. Unlike other members of this family, no unique receptor has yet been identified for it. It is extensively distributed throughout the body. It causes hypotension when given peripherally, but when given into the CNS, it increases blood pressure and causes sympathetic activation. It also increases prolactin release, is anti-diuretic and natriuretic and reduces food intake. Whilst its effects resemble those of AM, it is frequently more potent. Some characterization of AM2 has been done on molecularly defined receptors; the existing data suggest that it preferentially activates the AM receptor formed from calcitonin receptor-like receptor and receptor activity modifying protein 3. On this complex, its potency is generally equivalent to that of AM. There is no known receptor-activity where it is more potent than AM. In tissues and in animals it is frequently antagonised by CGRP and AM antagonists; however, situations exist in which an AM2 response is maintained even in the presence of supramaximal concentrations of these antagonists. Thus, there is a partial mismatch between the pharmacology seen in tissues and that on cloned receptors. The only AM2 antagonists are peptide fragments, and these have limited selectivity. It remains unclear as to whether novel AM2 receptors exist or whether the mismatch in pharmacology can be explained by factors such as metabolism. © 2011 The British Pharmacological Society.

AB - Adrenomedullin 2 (AM2) or intermedin is a member of the calcitonin gene-related peptide (CGRP)/calcitonin family of peptides and was discovered in 2004. Unlike other members of this family, no unique receptor has yet been identified for it. It is extensively distributed throughout the body. It causes hypotension when given peripherally, but when given into the CNS, it increases blood pressure and causes sympathetic activation. It also increases prolactin release, is anti-diuretic and natriuretic and reduces food intake. Whilst its effects resemble those of AM, it is frequently more potent. Some characterization of AM2 has been done on molecularly defined receptors; the existing data suggest that it preferentially activates the AM receptor formed from calcitonin receptor-like receptor and receptor activity modifying protein 3. On this complex, its potency is generally equivalent to that of AM. There is no known receptor-activity where it is more potent than AM. In tissues and in animals it is frequently antagonised by CGRP and AM antagonists; however, situations exist in which an AM2 response is maintained even in the presence of supramaximal concentrations of these antagonists. Thus, there is a partial mismatch between the pharmacology seen in tissues and that on cloned receptors. The only AM2 antagonists are peptide fragments, and these have limited selectivity. It remains unclear as to whether novel AM2 receptors exist or whether the mismatch in pharmacology can be explained by factors such as metabolism. © 2011 The British Pharmacological Society.

KW - calcitonin

KW - CGRP

KW - adrenomedullin

KW - intermedin

KW - amylin

KW - calcitonin receptor-like receptor

KW - RAMP

KW - receptor activity-modifying protein

KW - prolactin

KW - hypotension

UR - http://www.scopus.com/inward/record.url?scp=84856528059&partnerID=8YFLogxK

UR - http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2011.01530.x/abstract

U2 - 10.1111/j.1476-5381.2011.01530.x

DO - 10.1111/j.1476-5381.2011.01530.x

M3 - Article

C2 - 21658025

VL - 166

SP - 110

EP - 120

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -